ArticleInternational journal of chronic obstructive pulmonary disease2025
miR-335-5p Predicts Elevated Chronic Obstructive Pulmonary Disease (COPD) Susceptibility and Its Role in Human Bronchial Epithelial Cells Injury.
Article in International journal of chronic obstructive pulmonary disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- miR-766-5p Attenuates Cigarette Smoke-Induced COPD by Targeting MAPK1.Journal of biochemical and molecular toxicology · 2026Article
- Pathogenesis and Risk Factors of Post-Infectious Bronchiolitis Obliterans in Children: A Focus on Adenovirus and Mycoplasma Infections.Pathogens (Basel, Switzerland) · 2026Review
- MiR-129-5p is associated with chronic obstructive pulmonary disease status and alleviates cigarette smoke extract-induced human bronchial epithelial cell injury.Tobacco induced diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Chronic obstructive pulmonary disease (COPD) suffers from high prevalence, disability and mortality rates and a heavy economic burden. miR-335-5p takes part in multiple respiratory diseases such as pulmonary fibrosis, whereas its study in COPD has not been reported. The aim of our research was to explore miR-335-5p in predicting elevated COPD susceptibility and in human bronchial epithelial cells injury. Patients and Methods: qRT-PCR was performed to examine miR-335-5p levels in serum and cells. ROC curve and logistic regression analyses were utilized to evaluate the predictive capacity of miR-335-5p for COPD susceptibility. Pearson correlation was used to assess the association of miR-335-5p with TNF-α, IL-6, FEV1, and FEV1/FVC. Human bronchial epithelial cells were exposed to cigarette smoke extract (CSE) conditions to simulate cell injury. Cell proliferation, apoptosis, inflammatory response and oxidative stress-related factors were assayed by CCK8, flow cytometry and ELISA, respectively. Results: miR-335-5p is reduced on COPD patients. ROC curve recommended that miR-335-5p has high sensitivity (88.9%) and specificity (80.0%) to distinguish COPD from healthy individuals. Logistic regression showed that reduced miR-335-5p predicted elevated COPD susceptibility. Moreover, miR-335-5p was significantly negatively related to TNF-α and IL-6 and positively related to FEV1, and FEV1/FVC in COPD patients. Cellular experiments revealed that CSE treatment decreased miR-335-5p expression, repressed cell proliferation, facilitated apoptosis, raised TNF-α, IL-6, ROS, and MDA levels, and reduced SOD levels. miR-335-5p overexpression facilitated cell proliferation, suppressed apoptosis, diminished TNF-α, IL-6, ROS, and MDA levels, and elevated SOD levels, whereas knockdown of miR-335-5p reversed this trend. Conclusion: Downregulation of miR-335-5p increased COPD susceptibility and negatively correlated with inflammatory factors. Overexpression of miR-335-5p alleviated CSE-induced injury to human bronchial epithelial cells, which suggested that miR-335-5p may be a potential target for COPD treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.